Search Results for Shkreli

Showing 1 – 7

The Next Emflaza: Acer Therapeutics Looks to Take a Page Out of Marathon's Book By Zachary Brennan - Published 18 January 2018

Last year, Marathon Pharmaceuticals took an inexpensive steroid available for sale in the EU and Canada and brought it through the US Food and Drug Administration's (FDA) approval process before trumpeting an $89,000 annual price.

Categories: News, US, FDA, Drugs, Regulatory intelligence, Regulatory strategy

Tags: Emflaza, Marathon, Acer, Shkreli

Arbitrary Pharmaceutical Price Gouging: Valeant Defends its Business Model By Zachary Brennan - Published 27 April 2016

As the anger over Martin Shkreli’s infamously steep and entirely arbitrary price hike of a rare disease drug has subsided, Congress has begun to turn its attention to other companies, such as Valeant Pharmaceuticals, which rely on price gouging as the foundation of their business models.

Categories: News, US, Business Skills, Crisis management, Drugs, Reimbursement

Tags: Shkreli, Valeant, Ackman, Pershing, Walgreens

Senators Slam Execs of Shkreli's Former Company Over Arbitrary Price Hike on Lifesaving Drug By Zachary Brennan - Published 17 March 2016

The Senate’s Special Committee on Aging held its second hearing on pharmaceutical pricing on Thursday, this time taking shots at executives of Martin Shkreli’s former company Turing Pharmaceuticals, which only exists because of a monopoly and 5,000% price hike on a toxoplasmosis drug first approved more than 50 years ago.

Categories: News, US, Crisis management, Drugs, Reimbursement, Research and development

Tags: Martin Shkreli, Turing, Retrophin, Kalobios, Senate Aging Committee

House Hearing Focuses on Harm Done by Drug Price Spikes By Zachary Brennan - Published 04 February 2016

The highly anticipated House Oversight Committee hearing on Thursday was not without its fireworks, though beyond the airing of a lot of discontent, few new options for halting drug price increases were brought to the table.

Categories: News, US, FDA, Drugs, Ethics, Government affairs, Reimbursement

Tags: Shkreli, Oversight hearing, Turing Pharmaceuticals, Valeant Pharmaceuticals

Congress Offers New Details on Drug Price Spikes By Zachary Brennan - Published 02 February 2016

Ahead of a Thursday hearing with US Food and Drug Administration (FDA) CDER Director Janet Woodcock sitting beside former Turing CEO Martin Shkreli, the House Oversight Committee has released documents where the former hedge fund manager calls the price hikes of a toxoplasmosis treatment “a very handsome investment.”

Categories: News, US, FDA, FTC, Active pharmaceutical ingredients, Business and Leadership, Drugs, Reimbursement

Tags: toxoplasmosis, Daraprim, Shkreli, drug price increases

Regulatory Recon: Shkreli Arrested on Securities Fraud Charges (17 December 2015) Published 17 December 2015

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. Want to read Recon as soon as it's posted? Follow @Michael_Mezher, @Zachary Brennan and @RAPSorg on Twitter.

Categories: News, Africa, Asia, Canada, Europe, Latin America and Caribbean, Oceania, US, Anvisa, CDSCO, DOJ, EMA, FDA, MHRA, TGA, Biologics and biotechnology, Business Skills, Combination products, Crisis management, Distribution, Drugs, Ethics, Government affairs, Manufacturing, Medical Devices, Quality

Tags: Shkreli, generic drug pricing, Sarepta, biosimilars

Senate Committee Considers Priority Reviews to Stem the Tide of Off-Patent Drug Price Hikes By Zachary Brennan - Published 09 December 2015

Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Mo.) hosted a hearing Wednesday to discuss steep price increases for off-patent drugs and what can be done to ensure patients and hospitals can afford these drugs moving forward.

Categories: News, US, FDA, FTC, Crisis management, Drugs, Ethics, Government affairs, Manufacturing, Reimbursement

Tags: drug pricing, Martin Shkreli, Turing, Daraprim, off patent drug prices, Senate committee